Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose Escalation Study of Once-daily Oral Treatment With BIBF 2992 for 21 Days in Patients With Advanced Solid Tumors

NCT02171663 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02171663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02171663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose Escalation Study of Once-daily Oral Treatment With BIBF 2992 for 21 Days in Patients With Advanced Solid Tumors
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2004
Completion date
Not reported
Enrollment
43 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms